Ninety One UK Ltd Acquires 11,890 Shares of Danaher Corporation $DHR

Ninety One UK Ltd lifted its holdings in Danaher Corporation (NYSE:DHR) by 22.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 64,880 shares of the conglomerate’s stock after purchasing an additional 11,890 shares during the quarter. Ninety One UK Ltd’s holdings in Danaher were worth $14,374,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Veery Capital LLC grew its holdings in Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after acquiring an additional 48 shares during the last quarter. Studio Investment Management LLC raised its stake in shares of Danaher by 3.3% in the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after acquiring an additional 51 shares during the last quarter. JDH Wealth Management LLC raised its stake in shares of Danaher by 4.5% in the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after acquiring an additional 55 shares during the last quarter. OLD Second National Bank of Aurora raised its stake in shares of Danaher by 0.5% in the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock worth $2,297,000 after acquiring an additional 57 shares during the last quarter. Finally, Adelphi Trust Co lifted its position in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock worth $524,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Evercore reissued an “outperform” rating and set a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. UBS Group initiated coverage on shares of Danaher in a report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price target for the company. Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Price Performance

Shares of DHR stock opened at $231.52 on Friday. The firm has a market cap of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $213.55 and a 200 day moving average price of $195.74.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.77 EPS. Research analysts expect that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.